AUPH (Aurinia Pharmaceuticals) Total Receivables: $49.2 Mil (As of Mar. 2026)


AUPH Aurinia Pharmaceuticals Inc AUPH
81 GF Score
Price $15.85
GF Value $14.01
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Aurinia Pharmaceuticals Total Receivables?

Aurinia Pharmaceuticals AUPH +1.51% 81 Total Receivables is $49.2 Mil as of Mar. 2026. GuruFocus rates AUPH with a GF Score™ of 81/100 and a GF Value™ of $14.01 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Aurinia Pharmaceuticals's Total Receivables for the quarter that ended in Mar. 2026 was $49.2 Mil.

Aurinia Pharmaceuticals Total Receivables Related Terms

Aurinia Pharmaceuticals Total Receivables Historical Data

* Premium members only.

The historical data trend for Aurinia Pharmaceuticals's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aurinia Pharmaceuticals Total Receivables Chart

Aurinia Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.41 13.48 24.09 36.54 41.45

Aurinia Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 40.35 40.09 30.73 41.45 49.18
AUPH
81GF Score
Aurinia Pharmaceuticals Inc AUPH
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aurinia Pharmaceuticals Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $49.2 Mil mean?
Aurinia Pharmaceuticals (AUPH) has a Total Receivables of $49.2 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Aurinia Pharmaceuticals and its competitors.
Is Aurinia Pharmaceuticals' Total Receivables too high?
Aurinia Pharmaceuticals' current Total Receivables is $49.2 Mil. Overall, Aurinia Pharmaceuticals has a GF Score™ of 81/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aurinia Pharmaceuticals' Total Receivables compare to KOD and ABCL?
Aurinia Pharmaceuticals' Total Receivables of $49.2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Aurinia Pharmaceuticals and its competitors. Aurinia Pharmaceuticals's current Total Receivables is $49.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurinia Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Aurinia Pharmaceuticals (AUPH) is currently considered Modestly Overvalued. The stock's GF Value™ is $14.01, compared to a current price of $15.85 — trading 13.1% above its estimated fair value. The current Total Receivables is $49.2 Mil. Aurinia Pharmaceuticals' overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Aurinia Pharmaceuticals (AUPH), the current Total Receivables is $49.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aurinia Pharmaceuticals (AUPH) Overvalued in 2026?

Based on GuruFocus' analysis, Aurinia Pharmaceuticals stock appears to be overvalued. The current stock price of $15.85 is trading 13.1% above its estimated GF Value™ of $14.01. GuruFocus considers Aurinia Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for AUPH:

  • Total Receivables: $49.2 Mil
  • GF Value™: $14.01 vs. price of $15.85 (13.1% above fair value)
  • GF Score™: 81/100 with 4 warning signs

No single metric tells the full story. See the AUPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aurinia Pharmaceuticals Business Description

Other Exchanges IKAP:Germany
Address 14315 - 118 Avenue, Suite 140, Edmonton, AB, CAN, T5L 4S6
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
81GF Score

Get the complete analysis for AUPH

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.85
Price
$14.01
GF Value